Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
BackgroundUnresectable hepatocellular carcinoma (u-HCC) still accounts for the majority of newly diagnosed HCC which with poor prognosis. In the era of systemic therapy, combination therapy with programmed cell death protein-1 (PD-1) inhibitors and tyrosine kinase inhibitors (TKIs) has become mainst...
Main Authors: | Laihui Luo, Yongqiang Xiao, Guoqing Zhu, Aihong Huang, Shengjiang Song, Tao Wang, Xian Ge, Jin Xie, Wei Deng, Zhigao Hu, Wu Wen, Haoran Mei, Renhua Wan, Renfeng Shan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1004652/full |
Similar Items
-
Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review
by: Marco Massani, et al.
Published: (2021-06-01) -
Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
by: Yajing Wang, et al.
Published: (2023-06-01) -
Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
by: Long T, et al.
Published: (2023-10-01) -
A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy
by: Baojiang Liu, et al.
Published: (2023-08-01) -
Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
by: Jinpeng Li, et al.
Published: (2023-07-01)